STOCK TITAN

BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

BioMarin (NASDAQ: BMRN) will host a conference call and webcast on Monday, May 4, 2026 at 4:30 p.m. ET to discuss first quarter 2026 financial results and provide a general business update. Alexander Hardy, president and CEO, will host the call.

Dial-in and replay numbers are provided and a live audio webcast and one-week replay will be available via the investor site: https://investors.biomarin.com/.

Loading...
Loading translation...

AI-generated analysis. Not financial advice.

Positive

  • None.

Negative

  • None.

News Market Reaction – BMRN

+1.18%
1 alert
+1.18% News Effect

On the day this news was published, BMRN gained 1.18%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

2025 total revenue: $3.22B Q4 2025 revenue: $875M VOXZOGO revenue: $927M +5 more
8 metrics
2025 total revenue $3.22B Full-year 2025, up 13% year-over-year
Q4 2025 revenue $875M Fourth quarter 2025, up 17% year-over-year
VOXZOGO revenue $927M Full-year 2025 product revenue, up 26%
Enzyme Therapies revenue $2.105B Full-year 2025 segment revenue, up 9%
2026 revenue guidance $3.325–3.425B Total revenues guidance for 2026, excluding Amicus
2026 EPS guidance $4.95–5.15 Non-GAAP diluted EPS guidance for 2026, excluding Amicus
Amicus acquisition value $4.8B All-cash agreement to acquire Amicus Therapeutics
Inozyme acquisition value $270M Completed acquisition of Inozyme Pharma

Market Reality Check

Price: $55.97 Vol: Volume 1,080,169 is below...
low vol
$55.97 Last Close
Volume Volume 1,080,169 is below the 20-day average of 1,568,621 ahead of the call announcement. low
Technical Shares at $53.18 are trading below the 200-day MA of $56.47 and nearer the 52-week low of $50.76 than the high of $66.28.

Peers on Argus

BMRN was down 1.48% pre-announcement, while peers showed mixed moves: BBIO appea...
1 Up 1 Down

BMRN was down 1.48% pre-announcement, while peers showed mixed moves: BBIO appeared in momentum scanners up about 5.08% and RPRX down about 3.70%, indicating stock-specific dynamics rather than a broad biotech move.

Previous Conferences,earnings Reports

5 past events · Latest: Feb 17 (Neutral)
Same Type Pattern 5 events
Date Event Sentiment Move Catalyst
Feb 17 Earnings call notice Neutral +0.1% Announced Q4 and full-year 2025 results call and webcast timing.
Jul 22 Earnings call notice Neutral +4.7% Scheduled Q2 2025 financial results call with webcast access details.
Apr 17 Earnings call notice Neutral +0.6% Set date and time for Q1 2025 financial results call and update.
Feb 05 Earnings call notice Neutral +2.1% Announced Q4 2024 and full-year 2024 results call and webcast details.
Oct 16 Earnings call notice Neutral -0.4% Announced Q3 2024 financial results call with replay information.
Pattern Detected

Scheduling earnings calls and webcasts has historically led to modest, mostly positive price reactions, suggesting these notices are treated as routine but slightly constructive catalysts.

Recent Company History

Recent news for BioMarin highlights steady operational progress and recurring communication around financial results. Prior conference call scheduling announcements in 2024 and 2025 produced small mostly positive moves between roughly flat and mid-single digits. Alongside this, the company has reported growing revenues, product data, regulatory approvals, and strategic transactions. Today’s announcement of a Q1 2026 results call fits this established pattern of routine investor communications ahead of detailed earnings releases.

Historical Comparison

+1.4% avg move · In past conferences/earnings call notices, BMRN saw an average move of about 1.41%, suggesting today...
conferences,earnings
+1.4%
Average Historical Move conferences,earnings

In past conferences/earnings call notices, BMRN saw an average move of about 1.41%, suggesting today’s Q1 2026 call announcement fits a historically low-volatility pattern for this tag.

The company has consistently pre-announced quarterly conference calls and webcasts, maintaining a regular cadence of earnings communications from Q3 2024 through full-year 2025 into Q1 2026.

Market Pulse Summary

This announcement sets the schedule for BioMarin’s first quarter 2026 financial results call on May ...
Analysis

This announcement sets the schedule for BioMarin’s first quarter 2026 financial results call on May 4, 2026 at 4:30 p.m. ET, continuing its pattern of regular quarterly communications. Historical earnings call notices under the same tag have produced modest average moves of about 1.41%. Investors may focus on how upcoming results align with prior 2025 revenues of $3.22B, 2026 guidance ranges, and integration of recent acquisitions.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

SAN RAFAEL, Calif., April 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m. ET to discuss first quarter 2026 financial results and provide a general business update.

Dial-in Number
U.S. / Canada Dial-in Number: 800-715-9871
International Dial-in Number: 646-307-1963
Conference Call ID: 3424435 

U.S. / Canada Replay Dial-in Number: 800-770-2030
International Replay Dial-in Number: 609-800-9909
Playback ID: 3424435  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.

About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with a portfolio of commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.  

Contacts:






Investors

Media


Traci McCarty

Marni Kottle


BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.


(415) 455-7558

(650) 374-2803


 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-monday-may-4-2026-at-430pm-et-302753431.html

SOURCE BioMarin Pharmaceutical Inc.

FAQ

When will BioMarin (BMRN) discuss its first quarter 2026 results?

The call is scheduled for Monday, May 4, 2026 at 4:30 p.m. ET. According to the company, Alexander Hardy will host and provide a general business update alongside the Q1 2026 financial results.

How can investors join the BioMarin (BMRN) May 4, 2026 conference call?

Investors can join via toll-free dial-in or international numbers and a live audio webcast. According to the company, the webcast is accessible through https://investors.biomarin.com/ in the investor relations section.

What are the dial-in and replay details for the BioMarin (BMRN) earnings call?

Primary U.S./Canada dial-in is 800-715-9871 and international dial-in is 646-307-1963. According to the company, replay numbers and a playback ID will be provided and archived for one week after the call.

Will BioMarin (BMRN) provide a webcast and how long will the replay be available?

Yes. A live audio webcast will be available and a replay will be archived for one week after the call. According to the company, the webcast and replay can be accessed via the investor site at investors.biomarin.com.

Who will host the BioMarin (BMRN) first quarter 2026 conference call?

Alexander Hardy, BioMarin's president and CEO, will host the call. According to the company, he will discuss first quarter 2026 financial results and provide a general business update during the May 4, 2026 webcast.